

REMARKS

Status of the claims

Claims 6, 8-9, 13, 15, and 20-23 have been canceled .

Claims 1-5, 7, 10-12, and 16-19 are pending.

Amendments

Claims 1-5, 7, 10-12, and 16-19 have been found allowable with regard to the elected group and have been amended to put them in compliance with the Examiner's restriction requirement. Variable A₁ has been defined in claim 1, and has basis in original claim 1. Variables and claims made unnecessary by the restriction have been eliminated. The scope of the claims has not been broadened thereby, nor has new material been added. It is requested that the objection to these claims be withdrawn.

Applicants do not agree that claims 20-23 are indefinite as the Examiner contends, but are canceling these claims in order to expedite issuance of this application. Applicants reserve the right to pursue unelected and/or unclaimed (including canceled) subject matter in subsequent divisional or continuing applications:

FEES


No fees should be due. However, if it is determined that a fee is due, please charge same to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

SUMMARY

Applicants believe the claims are now in condition for allowance and request issuance of the above-referenced application. The Examiner is invited to contact the undersigned by telephone, at the number listed below, if it is believed that a telephonic communication would facilitate the prosecution of this application.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5323


Laurelee A. Duncan
Attorney for Applicants
Reg. No. 44,096

October 3, 2005